In a review article in the October 2012 issue of the journal of Alimentary Pharmacology and Therapeutics, common substances in dietary supplements were reviewed for potential hepatotoxicity. The authors cite Herbalife cases in this review, which represent a broad range of onset dates between 1998 and 2010 as if they are current cases, and Herbalife is a specific agent.
Herbalife is a brand name for many different products, including cosmetics, foods and dietary supplements and none of the case reports referenced to date have one ingredient or product in common. Some of the case reports even involve products that are no longer marketed by Herbalife.
Herbalife has raised the aforementioned concerns and objected to other misconceptions about our products through various rebuttal articles.[2-7] The authors revisit many of these same issues. However, only two of our rebuttals are referenced by the authors, reflecting an unbalanced analysis.
The authors also erroneously state that US manufacturers of dietary supplement/herbal products do not have a regulatory obligation to report adverse events to the Food and Drug Administration (US FDA). The requirement for dietary supplement manufacturers to monitor and report serious adverse event reports to FDA has been effective since 22 December 2007.
Finally, the authors cite a reference to intimate that Herbalife has not been communicative, when our attempts to establish transparency with the scientific community actually precede the date of the reference cited by these authors. In fact, Herbalife has cooperated with 27 countries to address liver-related cases and articles in the literature. After more than 30 years in business, none of the 27 agencies has taken any regulatory action affecting Herbalife products. We invite the authors from this article to engage in further review of these cases with our representatives as well.